Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas

Abstract
Background: Meningiomas consist of 15%–30% of the primary intracranial tumors, and high-grade meningiomas have a higher recurrence after surgery. The human epidermal growth factor receptor 2 (HER2) status is important in the medical management of patients with various human cancers. This study aimed to evaluate HER2 expression in meningiomas and the correlation between this expression and age, gender, and grade. Materials and Methods: In a descriptive-analytic study, immunohistochemistry (IHC) with HER2 marker was done on confirmed cases of meningioma which were referred to the pathology laboratory from 2008 to 2015. The primary antihuman antibody against c-erbB-2 oncoprotein (DAKO Diagnostics) was used for IHC. Results: Of 117 patients, 68.4% were males. The mean age of the patients was 53.6 years. Grades I, II, and III tumors were 90.6%, 8.5%, and 0.9% of cases, respectively. Totally, 76 (65%) of patients were HER2 positive, with only 7.7% of highly expressed HER2. There was no significant correlation between the mean age (P = 0.672), age group (P = 0.256), sex (P = 0.574), and grade (P = 0.093) and HER2 expression status. Conclusions: We did not find a statistically significant correlation between age, sex, or grade and HER2 status; however, further studies with a higher number of Grades II and III meningiomas and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.

Keywords: Human epidermal growth factor receptor 2, immunohistochemistry, meningioma

Introduction
Meningiomas include between 15% and 30% of the primary intracranial tumors with an annual incidence of 5/100,000.[1,2] These tumors develop more in middle and late adulthood.[3] Meningiomas were graded into three groups (Grade I: benign), (Grade II: atypical), and (Grade III: anaplastic or malignant).[4] Most meningiomas are benign tumors, but up to 15% are atypical, and 2% malignant according to the World Health Organization histological criteria reported in 2016.[2] Meningiomas more often afflict women than men and are rare but often aggressive in children.[1,3,5] Despite the molecular mechanisms of meningioma having been described, the curative effects of current treatments for invasive and malignant meningiomas have been unsatisfactory.[6] Tumor recurrence was observed in 7%–20% of Grade I, 29%–40% of Grade II, and 50%–78% of Grade III meningiomas, following surgery. Due to high tumor recurrence in Grade II/III meningiomas, additional treatment protocols with targeted therapy may be required with the available chemotherapeutic drugs.[7,8] The human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a 185-kD transmembrane glycoprotein with tyrosine kinase activity expressed in meningiomas and various other tumors.[9] HER2 status is important in the medical management of patients with various human cancers[8] and can be a therapeutic target with monoclonal antibodies for meningiomas that interact with HER2 receptors,[9,10] but the prognostic value of this receptor protein in meningiomas is ambiguous.[10,11] This study aimed to evaluate the HER2 expression in meningiomas and the correlation between this expression and age, gender, and grade.

Materials and Methods
Specimen selection
In this descriptive-analytic study, paraffin blocks were checked in patients with meningiomas admitted to the pathology laboratory of Imam Reza Hospital.

Mazaher Ramezani1, Hanieh Firoozabadi2, Mansour Rezaei3, Sedigheh Khazaei4, Masoud Sadeghi4
1Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran, 2Department of Biostatistics, Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, 3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, 4Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kermanshah, Iran, from 2008 to 2015. After referring to the computer file and the offices in the pathology laboratory, the samples were selected to reach a sufficient sample size (117 samples).

Immunochemistry

At first, hematoxylin and eosin (H and E)-stained slides were collected from each sample from the archives and then the paraffin blocks were prepared by 4-μ sections for the H and E routine staining and immunohistochemistry (IHC) staining with the HER2 marker. The tissue sections were reexamined by the pathologist and the diagnosis of meningioma was confirmed. Then, IHC specimens were examined. Primary anti-human antibody against c-erbB-2 oncoprotein (DAKO Diagnostics, Polyclonal Rabbit Antihuman c-erbB-2 Oncoprotein, Code A0485) was used for the IHC. According to the pattern of staining, the specimen was marked as IHC0 (less than 10% of the tumor cells were stained; negative), IHC1+ (more than 10% of the tumor cells were stained and the membrane of the cells was incomplete and poorly stained, negative), IHC2+ (more than 10% of the tumor cells were stained and the cell membrane was full but weak-to-medium staining, ambiguous, or duplex), and IHC3+ (more than 10% of the tumor cells were stained and the cell membrane was full and strong staining, positive). Then, the results were recorded in the data collection form. We considered score 0 and 1+ as negative, while those with score 2+ and 3+ considered as positive. A ductal carcinoma of the breast (in which the intense and high percentages of cells were stained for the HER2 marker) was used as a positive control. IHC and a normal breast sample as a negative control. Figure 1 demonstrates IHC staining patterns in meningiomas.

Statistical analysis

The data were analyzed by SPSS version 22 (IBM Corp., Armonk, NY, USA) and by binary logistic regression (odds ratio [OR] and 95% confidence interval [CI]). \( P < 0.05 \) was considered to be statistically significant.

Ethical approval

This study was approved by the Ethics Committee of Kermanshah University of Medical Sciences, Kermanshah, Iran. The names of the patients remained confidential, and no additional costs were imposed on patients.

Results

The mean age of patients was 53.6 years (range, 1–88 years); 68.4% were males and 31.6% were females. Meningiomas were most common in the 6th to 7th decades of life. 106 patients (90.6%) had Grade I, 10 (8.5%) had Grade II, and 1 (0.9%) had Grade III. With regard to HER2 expression, 4 (3.4%) had IHC0, 37 (31.6%) IHC1+, 67 (57.3%) IHC2+, and 9 (7.7%) IHC3+. Totally, 76 (65%) patients were HER2 positivity and 41 (35%) were negativity.

A comparison between three variables with HER2 expression status by binary logistic regression is shown in Table 2. The results showed that there was no significant correlation between the mean age (OR = 1.012; 95% CI: 0.967, 1.060; \( P = 0.605 \)), age group (OR = 0.552; 95% CI: 0.158, 1.935; \( P = 0.353 \)), sex (OR = 1.123; 95% CI: 0.482, 2.615; \( P = 0.788 \)), and grade (OR = 0.655; 95% CI: 0.179, 2.399; \( P = 0.523 \)) with HER2 expression status.

Discussion

Meningiomas are caused by arachnoid cells, and typically, these tumors are slow-growing lesions, but the recurrence followed by surgical treatment is a problem with which they are faced.[1] Understanding the invasive molecular mechanism may help design appropriate treatments and increase survival rates.[2] Due to the significant recurrence rate, including Grades I and II, treatment for meningiomas requires modalities such as existing drugs.[1] Meanwhile, in all cases of meningioma, there is no possibility of complete resection of the lesion, and the remainder of the tumor may not be controlled by radiotherapy. Therefore, targeted molecular therapies for the effects on meningiomas can be very beneficial, especially if you need to reduce neurological interventions.[3,4] In this regard, the HER2 family is noteworthy that they are effective tyrosine kinase receptors in a tumorigenic activity.[3] These receptors play important roles in the direction of the cell signal involved in cell growth.[5] The family of tyrosine kinase growth factor receptors, in addition to HER2, also contains HER1, HER3, and HER4.[5,6] Excessive expression of the HER2 gene has been found in many different types of human malignancies, including the breast, lung, ovary, stomach, pancreas, prostate, and colorectal, and cancers of the female genital tract, with a poor prognosis in at least a few of them.[1,6,7] Previous studies have shown a different...
In a study by Anderson et al., the expression of the HER2 family in relation to various parameters in 44 glioma and 26 meningioma samples was analyzed using real-time polymerase chain reaction; the expressions of HER1, HER2, and HER4 in the majority of meningiomas were observed. However, HER3 was found only in one of the samples. In addition, the immunohistochemical method showed a high expression of HER2 in meningiomas. In a study by Mahzouni and Movahedipour using immunohistochemical methods and in a retrospective study, 31 of 72 samples of meningiomas (43%) were HER2 positivity (55% of Grades II or III and 38.5% of Grade I samples). Although Grade II meningiomas showed a higher HER2 protein immunoreactivity, this difference was not statistically significant. In this study, HER2 expression was seen in 39% male and 44.9% female samples, but there was no statistically significant difference between the two genders. In a 2008 study by Durand et al., on human meningiomas, the association of the expression of HER2 gene with gradient and histologic grade of the tumor was investigated that the levels of mRNA of this gene did not correlate with histological grade. One study on 100 samples of meningioma (including 80 samples of Grade I, 18 of Grade II, and 2 of Grade III) investigated the association between HER2 expression and sex, location, grade, and subtypes of meningiomas. According to the results of this study, HER2 positivity was seen in 73% of the samples (75% of Grade I, 72.2% of Grade II, and 0% of Grade III samples). There was no significant association between HER2 expression and the mentioned factors. Another study checked the expression of HER2 in 60 meningioma samples (48 samples with Grade I and 12 samples with Grades II or III) using IHC and the relationship between the expression of HER2 and sex, age, tumor grade, and recurrence or regrowth. HER2 positivity was seen in 88.3% of the samples (31.7% – weak, 38.3% – moderate, and 18.3% – strong). There was no statistically significant difference between sex, age, tumor grade, and recurrence and HER2 expression. Of 186 human meningiomas of all malignancy grades that 163 of these were in tissue microarrays, about 48% and 11% were HER2 positivity in the meningiomas, and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.

**Table 1: The baseline characteristics of the patients**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>53.6±13.4</td>
</tr>
<tr>
<td></td>
<td>Range 1–88</td>
</tr>
<tr>
<td>≤50/&gt;50 (%)</td>
<td>47 (40.2)/70 (59.8)</td>
</tr>
<tr>
<td>Sex (%)</td>
<td>Male 80 (68.4)</td>
</tr>
<tr>
<td></td>
<td>Female 37 (31.6)</td>
</tr>
<tr>
<td>Grade (%)</td>
<td>I 106 (90.6)</td>
</tr>
<tr>
<td></td>
<td>II 10 (8.5)</td>
</tr>
<tr>
<td></td>
<td>III 1 (0.9)</td>
</tr>
<tr>
<td>HER2 expression (%)</td>
<td>0 4 (3.4)</td>
</tr>
<tr>
<td></td>
<td>1+ 37 (31.6)</td>
</tr>
<tr>
<td></td>
<td>2+ 67 (57.3)</td>
</tr>
<tr>
<td></td>
<td>3+ 9 (7.7)</td>
</tr>
<tr>
<td>HER2 status (%)</td>
<td>Positive 76 (65)</td>
</tr>
<tr>
<td></td>
<td>Negative 41 (35)</td>
</tr>
</tbody>
</table>

**Table 2: The correlation between the variables with human epidermal growth factor receptor 2 expression status (human epidermal growth factor receptor 2 positive and human epidermal growth factor receptor 2 negative) based on the binary logistic regression**

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.012 (0.967, 1.060)</td>
<td>0.605 (OR)</td>
</tr>
<tr>
<td>Sex</td>
<td>1.523 (0.655, 2.399)</td>
<td>0.788 (Male versus female)</td>
</tr>
<tr>
<td>Grade</td>
<td>0.523 (0.655, 2.399)</td>
<td>0.353 (≤50 versus &gt;50)</td>
</tr>
</tbody>
</table>

OR – Odds ratio; CI – Confidence interval; SD – Standard deviation

level of HER2 expression in various types of brain tumors. Some studies have reported the high expression of this receptor in medulloblastoma and its association with poor prognosis in these tumors. HER2 protein has also been reported in the pituitary adenoma and vestibular schwannoma. In a study with work on human invasive specimens, expression and excessive activity of HER2 and HER3 were shown. In fact, only a few studies have done about the association between meningiomas and HER2 expression, and the results are different.

Wang et al. using IHC method showed that the expression of HER2 in benign meningiomas (no recurrence/initial), the benign recurrence group, the atypical group, and malignant group reported as follows: 35%, 30%, 15%, and 50%. It was also suggested in this study that higher tumor grade was associated with a higher expression of HER2 expression, and the HER2 gene amplification was reported in 7 of 26 samples (26.9%) of HER2 2+ meningiomas. In a study by Anderson et al., the expression of the HER2 family in relation to various parameters in 44 glioma and 26 meningioma samples was analyzed using real-time polymerase chain reaction; the expressions of HER1, HER2, and HER4 in the majority of meningiomas were observed. However, HER3 was found only in one of the samples. In addition, the immunohistochemical method showed a high expression of HER2 in meningiomas. In a study by Mahzouni and Movahedipour using immunohistochemical methods and in a retrospective study, 31 of 72 samples of meningiomas (43%) were HER2 positivity (55% of Grades II or III and 38.5% of Grade I samples). Although Grade II meningiomas showed a higher HER2 protein immunoreactivity, this difference was not statistically significant. In this study, HER2 expression was seen in 39% male and 44.9% female samples, but there was no statistically significant difference between the two genders. In a 2008 study by Durand et al., on human meningiomas, the association of the expression of HER2 gene with gradient and histologic grade of the tumor was investigated that the levels of mRNA of this gene did not correlate with histological grade. One study on 100 samples of meningioma (including 80 samples of Grade I, 18 of Grade II, and 2 of Grade III) investigated the association between HER2 expression and sex, location, grade, and subtypes of meningiomas. According to the results of this study, HER2 positivity was seen in 73% of the samples (75% of Grade I, 72.2% of Grade II, and 0% of Grade III samples). There was no significant association between HER2 expression and the mentioned factors. Another study checked the expression of HER2 in 60 meningioma samples (48 samples with Grade I and 12 samples with Grades II or III) using IHC and the relationship between the expression of HER2 and sex, age, tumor grade, and recurrence or regrowth. HER2 positivity was seen in 88.3% of the samples (31.7% – weak, 38.3% – moderate, and 18.3% – strong). There was no statistically significant difference between sex, age, tumor grade, and recurrence and HER2 expression. Of 186 human meningiomas of all malignancy grades that 163 of these were in tissue microarrays, about 48% and 11% were HER2 positivity in the meningiomas, and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.

**Conclusions**

In general, the high expression of HER2 in this study was found in 7.7% of meningiomas (9 of 117 samples). However, there was no significant difference between the expression of HER2 and sex, age, and tumor grade. Further studies with a higher number of Grade II and III meningiomas and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.
Acknowledgment

The authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences (Grant Number: 95355) for the financial support. The authors would like to thank the Clinical Research Development Center of Imam Reza Hospital for consulting services. This work was performed in partial fulfillment of the requirements for the degree of General Practitioner by Hanieh Firoozabadi at Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References